MX2013007657A - Oligodesoxinucleotidos inmunoestimulantes. - Google Patents

Oligodesoxinucleotidos inmunoestimulantes.

Info

Publication number
MX2013007657A
MX2013007657A MX2013007657A MX2013007657A MX2013007657A MX 2013007657 A MX2013007657 A MX 2013007657A MX 2013007657 A MX2013007657 A MX 2013007657A MX 2013007657 A MX2013007657 A MX 2013007657A MX 2013007657 A MX2013007657 A MX 2013007657A
Authority
MX
Mexico
Prior art keywords
oligodeoxynucleotides
immunostimulatory oligodeoxynucleotides
immunostimulatory
vaccines
medicament
Prior art date
Application number
MX2013007657A
Other languages
English (en)
Other versions
MX343048B (es
Inventor
Carla Christina Schrier
Thomas Simon Ilg
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2013007657A publication Critical patent/MX2013007657A/es
Publication of MX343048B publication Critical patent/MX343048B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención se refiere a oligodesoxinucleótidos inmunoestimulantes, vectores y vacunas que comprende dichos oligodesoxinucleótidos, para su uso como un medicamento, a su uso en la prevención o la lucha contra enfermedades infecciosas, a los métodos para la detección de tales oligodesoxinucleótidos y a las células para ser utilizadas en estos métodos.
MX2013007657A 2010-12-30 2011-12-29 Oligodesoxinucleotidos inmunoestimulantes. MX343048B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10197435A EP2471926A3 (en) 2010-12-30 2010-12-30 Immunostimulatory oligodeoxynucleotides
US201161430301P 2011-01-06 2011-01-06
PCT/EP2011/074211 WO2012089800A1 (en) 2010-12-30 2011-12-29 Immunostimulatory oligodeoxynucleotides

Publications (2)

Publication Number Publication Date
MX2013007657A true MX2013007657A (es) 2013-08-29
MX343048B MX343048B (es) 2016-10-21

Family

ID=44913150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007657A MX343048B (es) 2010-12-30 2011-12-29 Oligodesoxinucleotidos inmunoestimulantes.

Country Status (10)

Country Link
US (1) US9364531B2 (es)
EP (2) EP2471926A3 (es)
JP (2) JP5876889B2 (es)
CN (1) CN103270159B (es)
BR (1) BR112013016683A2 (es)
CA (1) CA2823065C (es)
MX (1) MX343048B (es)
RU (1) RU2615457C2 (es)
WO (1) WO2012089800A1 (es)
ZA (1) ZA201304712B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
TR201808393T4 (tr) 2011-05-26 2018-07-23 Intervet Int Bv İmmünostimülatör oligodeoksinükleotitler.
AR091569A1 (es) * 2012-06-28 2015-02-11 Intervet Int Bv Receptores de tipo toll
EP2754714A1 (en) * 2013-01-14 2014-07-16 Sarepta Therapeutics, Inc. Inhibitory oligonucleotides and their use in therapy
JP2016526532A (ja) 2013-06-14 2016-09-05 インターベット インターナショナル ベー． フェー． ＧｐＧオリゴデオキシヌクレオチドおよびサイクリックｄｉ‐ＧＭＰを含む医薬組成物
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
CN106794242B (zh) 2014-10-03 2021-11-30 英特维特国际股份有限公司 针对禽类呼肠孤病毒的广谱疫苗
CN105816868B (zh) * 2016-03-21 2020-01-03 青岛易邦生物工程有限公司 一种鸡滑液囊支原体灭活疫苗
KR20210068601A (ko) 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
CN106177937A (zh) * 2016-07-25 2016-12-07 江苏省农业科学院 鸡减蛋综合征和禽脑脊髓炎二联灭活疫苗及其制备方法
CN106177956B (zh) * 2016-08-29 2019-11-26 东北农业大学 提高鸡抗ndv病毒效果的方法
CA3084042A1 (en) * 2017-12-04 2019-06-13 Intervet International B.V. Vaccination with replicon particles and oil adjuvant
JP2021506246A (ja) 2017-12-15 2021-02-22 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ａｎｉｍａｌ Ｈｅａｌｔｈ Ｇｍｂｈ 免疫刺激性オリゴヌクレオチド
MX2020006343A (es) 2017-12-20 2020-09-03 Intervet Int Bv Diluyente mejorado para vacuna de herpesvirus alfa asociado con celulas.
CN110404064B (zh) * 2018-04-27 2023-06-16 洛阳赛威生物科技有限公司 一种禽用佐剂组合物及其制备方法
US20220023414A1 (en) 2018-12-20 2022-01-27 Intervet Inc. Prime-Boost Vaccination Regimen
JP2023506919A (ja) 2019-12-20 2023-02-20 インターベット インターナショナル ベー． フェー． 多価ｈｖｔベクターワクチン
WO2022136623A1 (en) 2020-12-24 2022-06-30 Intervet International B.V. Multivalent hvt vector vaccine
WO2023213946A1 (en) 2022-05-05 2023-11-09 Intervet International B.V. New multivalent hvt vector vaccine

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6552006B2 (en) 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
DK1450856T3 (da) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Pakning af immunstimulatorisk CpG i virus-lignende partilker, fremgangsmåde og anvendelse
SG167667A1 (en) * 2002-07-03 2011-01-28 Coley Pharm Group Inc Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
RU2338750C2 (ru) * 2002-08-19 2008-11-20 Коли Фармасьютикал Груп, Инк. ИММУНОСТИМУЛИРУЮЩИЕ ФОСФОРТИОАТНЫЕ CpG-ОЛИГОНУКЛЕОТИДЫ, СОДЕРЖАЩИЕ ФОСФОДИЭФИРНЫЕ СВЯЗИ, СПОСОБ ИММУНОМОДУЛЯЦИИ, СПОСОБ СТИМУЛИРОВАНИЯ ИММУННОГО ОТВЕТА
EP1575977B1 (en) * 2002-12-23 2009-09-09 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
ATE521621T1 (de) 2004-11-29 2011-09-15 Changchun Huapu Biotechnology Co Ltd Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
CN1810970B (zh) 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
WO2007020017A1 (en) 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
DE102006031483B4 (de) 2006-07-07 2009-12-24 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Zellulärer Pyrogentest
CA2687441A1 (en) * 2007-05-17 2008-11-27 Coley Pharmaceutical Group, Inc. Class a oligonucleotides with immunostimulatory potency
CA2695385A1 (en) * 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US9421254B2 (en) * 2007-09-24 2016-08-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunostimulatory combinations of TLR ligands and methods of use
US20100239523A1 (en) 2007-10-30 2010-09-23 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
TWI351288B (en) * 2008-07-04 2011-11-01 Univ Nat Pingtung Sci & Tech Cpg dna adjuvant in avian vaccines
EP2329845A4 (en) 2008-08-18 2013-08-14 Kitasato Daiichi Sankyo Vaccine Co Ltd BIRD GRAPEVIRUS ANTIGEN AND BOOSTER IMMUNIZATION PROCEDURE FOR BIRD FLUID VACCINE IN COMBINATION WITH A MUCOSAL ADJUVAN WITH EFFICACY THROUGH ORAL ADMINISTRATION
SG10201400388QA (en) 2008-12-09 2014-05-29 Pfizer Vaccines Llc IgE CH3 peptide vaccine
EP2424562B1 (en) * 2009-04-30 2015-10-07 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
EP2471926A3 (en) * 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
TR201808393T4 (tr) 2011-05-26 2018-07-23 Intervet Int Bv İmmünostimülatör oligodeoksinükleotitler.

Also Published As

Publication number Publication date
US20140205633A1 (en) 2014-07-24
EP2658974B1 (en) 2016-07-20
WO2012089800A1 (en) 2012-07-05
JP2014507131A (ja) 2014-03-27
JP5876889B2 (ja) 2016-03-02
CN103270159A (zh) 2013-08-28
RU2013135485A (ru) 2015-02-10
EP2471926A3 (en) 2012-07-11
CA2823065A1 (en) 2012-07-05
EP2658974A1 (en) 2013-11-06
ZA201304712B (en) 2014-03-26
BR112013016683A2 (pt) 2017-07-11
CN103270159B (zh) 2016-10-26
MX343048B (es) 2016-10-21
US9364531B2 (en) 2016-06-14
CA2823065C (en) 2019-03-05
EP2471926A2 (en) 2012-07-04
JP2016105707A (ja) 2016-06-16
RU2615457C2 (ru) 2017-04-04

Similar Documents

Publication Publication Date Title
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MY158992A (en) Forms of rifaximin and uses thereof
EP2706991A4 (en) IMMUNOGENIC COMPOSITION HAVING MULTIPLE ANTIGENS, METHODS AND USES THEREOF
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
MX2013004061A (es) Analogos de ciclosporina.
MX356210B (es) Formulaciones de polimero acrilico.
MX2013000522A (es) Formulaciones de rifaximina y usos de las mismas.
SG10201804817TA (en) Delayed release compositions of linaclotide
EP2596017A4 (en) PROTECTION AGAINST CROSS-REACTIVE DISEASES AND METHODS AND COMPOSITIONS THEREFOR
WO2013006569A3 (en) Herpes virus vaccine and methods of use
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
ZA201406382B (en) Levoisovalerylspiramycin i,ii,iii and preparations ,preparation methods and uses thereof
MX2013004062A (es) Analogos de ciclosporina.
WO2012065135A3 (en) Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
IN2015MN00038A (es)
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
EP2868317A4 (en) 2,2 ', 6,6'-TETRAISOPROPYL-4,4'-2-BIPHENOLIDE CAPSULE AND METHOD OF PREPARING THEREOF
MX2014015766A (es) Receptores de tipo toll y oligonucleotidos inmunoestimuladores.
GB2515222A (en) Use of flagellin as a vaccine
EP2929894A4 (en) VACCINE ADJUVANS, PREPARATION AND VACCINES THEREOF
HK1255682A1 (zh) 改性馬立克氏病病毒及從其製備的疫苗
MX350718B (es) Vacuna de rinitis equina.

Legal Events

Date Code Title Description
FG Grant or registration